We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

11 hedge funds and large institutions have $209K invested in Northwest Biotherapeutics, Inc. Common stock in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% less funds holding

Funds holding: 13 → 11 (-2)

27% less capital invested

Capital invested by funds: $286K → $209K (-$77.5K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
11
Holders Change
-2
Holders Change %
-15.38%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MSAM
Moloney Securities Asset Management
Missouri
+$12.1K

Top Sellers

Rank Fund Capital Flow
1
MWM
Maripau Wealth Management
Indiana
-$16.9K
2
SL
Sentinus LLC
Illinois
-$5.52K
Name Holding Trade Value Shares
Change 		Change in
Stake
MSAM
1
Moloney Securities Asset Management
Missouri
$148K +$12.1K +37,905 +9%
OCG
2
Opus Capital Group
Ohio
$19K – – –
WJWM
3
Williams Jones Wealth Management
New York
$11.2K – – –
EFG
4
Ethos Financial Group
Pennsylvania
$8K – – –
MCM
5
MAI Capital Management
Ohio
$6.4K – – –
LDB
6
Lee, Danner & Bass
Tennessee
$6K – – –
AA
7
AlphaMark Advisors
Kentucky
$4K – – –
KA
8
KLCM Advisors
Wisconsin
$3.2K – – –
AMG
9
Advisors Management Group
Wisconsin
$3K – – –
MWM
10
Maripau Wealth Management
Indiana
– -$16.9K -39,493 Closed
SL
11
Sentinus LLC
Illinois
– -$5.52K -12,925 Closed

NWBO Hedge Fund Activity: Q3 2024 in Review

11 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q3 2024, worth a combined $209K — down 27% from $286K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of NWBO and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Moloney Securities Asset Management, adding an estimated $12.1K. The largest seller was Maripau Wealth Management, exiting entirely with an estimated $16.9K sold.

  • 11 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q3 2024, down from 13 in Q2 2024.
  • Funds reported $209K of Northwest Biotherapeutics, Inc. Common stock stock for Q3 2024, down 27% quarter-over-quarter.
  • 0 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q3 2024 and 2 closed out, a net change of -2 holders.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q3 2024 was Moloney Securities Asset Management, an estimated $12.1K added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q3 2024 was Maripau Wealth Management, an estimated $16.9K sold.

Based on aggregated 13F filings for Q3 2024.